<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946074</url>
  </required_header>
  <id_info>
    <org_study_id>M14-006</org_study_id>
    <nct_id>NCT01946074</nct_id>
  </id_info>
  <brief_title>A Study of ABT-165 in Subjects With Solid Tumors</brief_title>
  <official_title>A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and
      preliminary efficacy of ABT-165 when administered as monotherapy and in combination with
      paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without
      paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B, C and D were
      completed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 8, 2013</start_date>
  <completion_date type="Anticipated">September 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical lab testing</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
    <description>Hematology, Chemistry, and Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of ABT-165</measure>
    <time_frame>Up to 90 days after a 24-month of treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The terminal elimination half life of ABT-165</measure>
    <time_frame>Up to 90 days after a 24-month treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac assessment</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
    <description>Electrocardiogram (ECG), echocardiogram (ECHO), basic natriuretic peptide (BNP) and troponin I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) form time zero to the last measurable concentration AUC (0-t)</measure>
    <time_frame>Up to 90 days after a 24-month treatment period</time_frame>
    <description>AUC (0-t) = Area under the serum concentration versus time curve form time zero (pre-dose) to the time of the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical exam</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
    <description>Assessment of normal/abnormal physical findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Up to 90 days after a 24-month treatment period</time_frame>
    <description>Collect all adverse events at each visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
    <description>Blood pressure, heart rate, respiratory rate and body temperature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
    <description>DOR is defined as the time from the subject's initial CR or PR to the time of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
    <description>ORR is defined as the proportion of the subjects who have a complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
    <description>PFS is defined as the time from the first dose date of ABT-165 to either disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-165 plus paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-165 plus FOLFIRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-165 plus ABBV-181</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-165 plus ABBV-181 plus paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel will be administered by intravenous infusion.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-165</intervention_name>
    <description>ABT-165 will be administered by intravenous infusion at escalating dose levels.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-181</intervention_name>
    <description>ABBV-181 will be administered by intravenous infusion.</description>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have advanced solid tumor that is not amenable to surgical resection or
             other approved therapeutic options that have demonstrated clinical benefit.

          -  Subject has adequate bone marrow, renal, hepatic and coagulation function.

          -  Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors
             (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including
             but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).

          -  Women of childbearing potential must have a negative serum pregnancy test at the
             screening visit and a negative urine pregnancy test at baseline prior to the first
             dose of study drug. Female subject considered not of childbearing potential must be
             documented as being surgically sterile or post-menopausal for at least 1 year. Women
             of childbearing potential and men must agree to use adequate contraception.

          -  Subjects in the combination therapy cohorts must meet the above inclusion criteria and
             be eligible to receive paclitaxel or FOLFIRI per most current prescribing information,
             or at the discretion of the Investigator. Subjects in the combination therapy cohorts
             who are to receive ABBV-181, an anti-PD1 antibody, must also meet other criteria
             described in the Protocol.

        Exclusion Criteria:

          -  Subject has received anticancer therapy including chemotherapy, radiation therapy,
             immunotherapy, biologic, or any investigational therapy within a period of 21 days or
             anti-cancer herbal therapy within 7 days prior to Cycle 1 Day 1 of ABT-165.

          -  Subject has uncontrolled metastases to the central nervous system (CNS).

          -  Subject has unresolved clinically significant toxicities from prior anticancer
             therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
             or higher.

          -  Subject has history (within previous 5 years) of clinically significant pulmonary
             hypertension, uncontrolled systemic hypertension or hypertensive crisis, symptomatic
             heart failure, cardiomyopathy, myocardial infarction, unstable/severe angina pectoris,
             cardiac arrhythmia requiring medication, coronary/peripheral artery bypass graft,
             aneurysm or aneurysm repair, angioplasty, cerebrovascular accident, transient ischemic
             attack or the left ventricular ejection fraction (LVEF) less than 50%.

          -  Subjects enrolled on the combination therapy phase must not meet the above exclusion
             criteria and must be eligible to receive paclitaxel or FOLFIRI per most current
             prescribing information, or at the discretion of the Investigator. Subjects receiving
             ABBV-181 must not meet other exclusion criteria described in the Protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth Research Institute - Pima /ID# 105677</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-2345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare /ID# 105678</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles /ID# 141389</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center - Main /ID# 141164</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Med /ID# 123758</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care, PC /ID# 151970</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research Center /ID# 138022</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center /ID# 105679</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology-Nashville Centennial /ID# 143280</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research /ID# 123757</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-181</keyword>
  <keyword>ABT-165</keyword>
  <keyword>cancer</keyword>
  <keyword>neoplasm</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

